2021 new and emerging treatment options: aml and minimal residual disease in blood cancers
Published 2 years ago • 3.4K plays • Length 1:31:30Download video MP4
Download video MP3
Similar videos
-
38:47
acute myeloid leukemia
-
1:03:30
new frontiers and emerging treatments for acute myeloid leukemia | webcast
-
50:44
2022 new emerging treatments: acute myeloid leukemia
-
58:32
significance of minimal residual disease in acute myeloid leukemia
-
1:11
are idh mutations good minimal residual disease (mrd) markers in acute myeloid leukemia (aml)?
-
28:29
novel therapies for acute myelogenous leukemia (aml)
-
58:08
aml: new emerging treatments
-
52:20
acute myeloid leukemia: incorporating novel treatment approaches into clinical pathways
-
1:22
dr. mannis talks about emerging treatments for acute myeloid leukemia
-
0:36
mrd studies in all and aml
-
2:16
the importance of mrd in aml prognosis and therapy
-
4:11
treatment options for newly diagnosed aml: venetoclax and midostaurin - blood cancer onctalk
-
1:13
blood cancer research: disparities in trials
-
4:43
mrd assessment and consolidation in aml
-
5:01
treatment options for high-risk aml
-
1:38
value of mrd in patients with npm1-mutated aml
-
4:03
impact of mrd on survival in aml
-
1:15:08
advances in blood cancer treatments
-
6:22
minimum residual disease in acute lymphoblastic leukemia